# Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible

> **NCT02261779** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Martin-Luther-Universität Halle-Wittenberg** · enrollment: 16 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Tranylcypromine
- **DRUG:** Tretinoin

## Key facts

- **NCT ID:** NCT02261779
- **Lead sponsor:** Martin-Luther-Universität Halle-Wittenberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2015-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261779, "Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02261779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*